Ira Pastan

27PUBLICATIONS
89CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Oct 16, 2026
EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial.

|Apr 22, 2024
A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin.

Anirban Chakraborty, Masanori Onda, Tara O'Shea

|Jan 16, 2024
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.

X F Liu, M Onda, J Schlomer

|Mar 27, 2023
Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies.

Jingyu Zhan, Dong Lin, Nathan Watson

|Feb 08, 2023
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.

Scott Parker, Charlotte McDowall, Luis Sanchez-Perez

|Nov 21, 2022
Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures.

Wenlong Liu, Chin-Hsien Tai, Xiufen Liu

Pageof 5

Frequent Collaborators

4 joint publications

Mitchell Ho

3 joint publications

Xiufen Liu

3 joint publications

Raffit Hassan

2 joint publications

Jingli Zhang